Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Breast Cancer Research and Treatment|August 9, 2013
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditionsDaniele Fanale, Viviana Bazan, Lidia Rita Corsini, et al.
Expert Opinion on Investigational Drugs|November 4, 2014
Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategyGiuseppe Bronte, Francesca Lo Vullo, Gianfranco Pernice, et al.
International Journal of Molecular Sciences|July 27, 2024
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case ReportDonato Michele Cosi, Cristina Fragale, Chiara Magri, et al.
Therapeutic Advances in Medical Oncology|May 31, 2016
Nintedanib in NSCLC: evidence to date and place in therapyGiuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Expert Review of Anticancer Therapy|April 26, 2016
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistanceAlessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.
Frontiers in Pharmacology|August 30, 2021
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung AdenocarcinomaCaterina Gianni, Giuseppe Bronte, Angelo Delmonte, et al.
Journal of Cellular Physiology|June 25, 2013
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancerTindara Franchina, Valeria Amodeo, Giuseppe Bronte, et al.
Translational Oncology|December 5, 2021
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, et al.
Expert Opinion on Investigational Drugs|June 25, 2013
BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancerChristian Rolfo, Luis E Raez, Giuseppe Bronte, et al.
Expert Opinion on Therapeutic Targets|September 24, 2013
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?Valeria Amodeo, Viviana Bazan, Daniele Fanale, et al.
Pageof 11